Device developer Coalesce Product Development has announced the appointments of Stephen Eason as Strategic Advisor and IP Consultant, and Mike Newton as Engineering Consultant.
Both men have extensive experience in the development of OINDP devices. Eason led development of the Aspirair dry powder inhaler while at Cambridge Consultants and joined Vectura as Senior Director, Device & Technology Development when Vectura acquired that device in 2002. Newton joined Vectura from Cambridge Consultants at the same time as Director, Device Industrialization.
In November 2016 Coalesce announced the appointments of former Vectura Director of IP and Corporate Affairs Colin Dalton as Chairman of the Board and inhalation expert James Tibbatts as Head of Business Development, as well as the opening of a new drug delivery development center in Cambridge, UK.
Coalesce CEO and Founder Dave Ahern commented, “We’ve known Stephen and Mike for many years and we are very excited to be working with them again. The specific knowledge and expertise that they bring enhances our growing capability in the drug delivery device space. As Coalesce continues to invest in infrastructure and human resources, and as we build reputation in the industry, Coalesce is emerging as a compelling option for pharmaceutical companies searching for turnkey drug delivery device development partners.”
Dalton commented, “We are delighted to be welcoming Stephen and Mike to Coalesce. They will be providing their invaluable support at a very exciting time as we continue to grow the business.”
Read the Coalesce Product Development announcement.